Tevogen Q2 2026: $11.2M Net Loss, $1.1M Cash, and New $11M CEO Stock Grant
TVGN sits 89% above its 52-week low of $3.636 on light trading volume (0.3× avg).
Summary
Tevogen's Q2 2026 filing shows a $11.2M net loss, $1.1M cash, and a subsequent $11M restricted stock grant to executives, including CEO Ryan Saadi.
Key Events · Earnings and Guidance · TVGN
-
Net Loss of $11.2M
For the six months ended June 30, 2026, Tevogen reported a net loss of $11.2 million, compared to $15.9 million in the prior year period.
-
Cash Position of $1.1M
Cash as of June 30, 2026 was $1.1 million, up from $0.6 million at year-end 2025, but the company remains reliant on related-party financing and grants.
-
Subsequent $11M Executive Stock Grant
On July 10 and July 21, 2026, the company issued 2,245,000 restricted shares under the 2024 Plan, including 1,220,000 to CEO Ryan Saadi, with a total grant date fair value of $11,075,000.
-
Nasdaq Delisting Risk
The company received notices from Nasdaq in April 2026 for failing the $50 million market value and $15 million public float requirements, with compliance deadlines in October 2026.
Analysis · TVGN · Life Sciences
Tevogen reported a net loss of $11.2 million for the first half of 2026, with only $1.1 million in cash as of June 30. The company disclosed a subsequent grant of 2.245 million restricted shares, including 1.22 million to CEO Ryan Saadi, valued at $11.1 million. This grant, combined with the company's ongoing Nasdaq delisting risk and reliance on related-party financing, highlights significant dilution and governance concerns for existing shareholders.
At the time of this filing, TVGN was trading at $6.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $44.1M. The 52-week trading range was $3.64 to $51.00. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.